TRAW (Traws Pharma) Tariff Resilience Score: 5/10 (As of Jul. 03, 2026)


TRAW Traws Pharma Inc TRAW
48 GF Score
Price $0.78
GF Value $12.94
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Traws Pharma Tariff Resilience Score?

Traws Pharma TRAW -5.34% 48 Tariff Resilience Score is 5 as of Jul. 03, 2026. GuruFocus rates TRAW with a GF Score™ of 48/100 and a GF Value™ of $12.94 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 1,373 Biotechnology companies, Traws Pharma ranks better than 62.27% on this metric.

Traws Pharma has the Tariff Resilience Score of 5, which implies that the company might have Average Resilient.

Traws Pharma has Traws Pharma relies on global supply chains for raw materials and manufacturing, exposing it to tariff risks. However, its ability to source from multiple suppliers and potential pricing power in niche markets provide some mitigation.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Traws Pharma might have Average Resilient.

Traws Pharma  (NAS:TRAW) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Traws Pharma Tariff Resilience Score Related Terms

TRAW vs ICU, INAB, CALC: Tariff Resilience Score Comparison

For the Biotechnology subindustry, Traws Pharma's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Traws Pharma Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Traws Pharma's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Traws Pharma's Tariff Resilience Score falls into.


TRAW
48GF Score
Traws Pharma Inc TRAW
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 5 mean?
Traws Pharma (TRAW) has a Tariff Resilience Score of 5 as of Jul. 03, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Traws Pharma ranks #518 out of 1373 companies in the Biotechnology industry, placing it in the top 37.7%.
Is Traws Pharma's Tariff Resilience Score too high?
Traws Pharma's current Tariff Resilience Score is 5. The Biotechnology industry median Tariff Resilience Score is 4.00. Traws Pharma's value of 5 is 25% above this industry median. Based on the distribution chart, Traws Pharma ranks #518 out of 1373 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Traws Pharma has a GF Score™ of 48/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Traws Pharma's Tariff Resilience Score compare to ICU and INAB?
According to the Biotechnology industry distribution chart, Traws Pharma ranks #518 out of 1373 companies for Tariff Resilience Score. This puts Traws Pharma in the upper half of its industry. The industry median Tariff Resilience Score is 4.00. Traws Pharma's value of 5 is 25% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,373 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Traws Pharma's current Tariff Resilience Score of 5 is 25% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Traws Pharma's current Tariff Resilience Score is 5. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Traws Pharma stock overvalued right now?
Based on GuruFocus' analysis, Traws Pharma (TRAW) is currently considered Possible Value Trap. The stock's GF Value™ is $12.94, compared to a current price of $0.78 — trading 93.9% below its estimated fair value. The current Tariff Resilience Score is 5 and 25% above the Biotechnology industry median of 4.00. Traws Pharma's overall GF Score™ is 48/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Traws Pharma (TRAW), the current Tariff Resilience Score is 5 as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Traws Pharma (TRAW) Overvalued in 2026?

Based on GuruFocus' analysis, Traws Pharma stock appears to be undervalued. The current stock price of $0.78 is trading 93.9% below its estimated GF Value™ of $12.94. GuruFocus considers Traws Pharma to be Possible Value Trap.

Key valuation signals for TRAW:

  • Tariff Resilience Score: 5
  • GF Value™: $12.94 vs. price of $0.78 (93.9% below fair value)
  • GF Score™: 48/100 with 4 warning signs
  • Industry Position: 25% above the Biotechnology median (#518 of 1373)

No single metric tells the full story. See the TRAW stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Traws Pharma Business Description

Address 12 Penns Trail, Newtown, PA, USA, 18940
Traws Pharma Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies to target critical threats to human health in respiratory viral diseases. It is advancing novel investigational antiviral agents that have potent activity against difficult-to-treat or resistant virus strains that threaten human health. Its product candidates are Tivoxavir marboxil, Ratutrelvir, and Narazaciclib. The company has four clinical programs: (i) tivoxavir marboxil, (ii) ratutrelvir, (iii) narazaciclib (ON 123300), and (iv) rigosertib. It is focused on the development of tivoxavir marboxil and ratutrelvir. The company derives revenue from its collaboration and licensing agreements.
48GF Score

Get the complete analysis for TRAW

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.78
Price
$12.94
GF Value